Cardiff Oncology(CRDF) - 2024 Q3 - Quarterly Results

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update - Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, November 7, 2024 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical ...